Who owns Xilio Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of XLO from SEC Form 13F filings across 29 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 29 institutions disclosed 3.1M shares of Xilio Therapeutics, Inc. worth $28.3M — about 15.9% of shares outstanding; the largest disclosed holder is Bain Capital Life Sciences Investors, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
29
13F holders
$28.3M
value, 2026 filers
15.9%
of shares outstanding (3.1M sh)
7
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of XLO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 664,021 | $6.0M | 0.4% | 3.4% | 0.0% |
| 2 | ORBIMED ADVISORS LLC | 592,300 | $5.4M | 0.1% | 3% | 0.0% |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 464,598 | $4.2M | 0.0% | 2.4% | +316.5% |
| 4 | Frazier Life Sciences Management, L.P. | 422,505 | $3.8M | 0.1% | 2.1% | 0.0% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 198,181 | $1.8M | 0.0% | 1% | +11.0% |
| 6 | Stonepine Capital Management, LLC | 189,092 | $1.7M | 1.1% | 1% | -16.3% |
| 7 | Sio Capital Management, LLC | 152,464 | $1.4M | 0.3% | 0.8% | 0.0% |
| 8 | Merck & Co., Inc. | 105,982 | $959,137 | 0.1% | 0.5% | 0.0% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 63,553 | $575,155 | 0.0% | 0.3% | -0.9% |
| 10 | MORGAN STANLEY | 53,674 | $485,750 | 0.0% | 0.3% | -5.8% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 41,449 | $375,140 | 0.0% | 0.2% | +6.1% |
| 12 | TWO SIGMA INVESTMENTS, LP | 40,104 | $362,941 | 0.0% | 0.2% | +175.7% |
| 13 | VANGUARD FIDUCIARY TRUST CO | 28,193 | $255,147 | 0.0% | 0.1% | +24.8% |
| 14 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 17,544 | $158,773 | 0.0% | 0.1% | 0.0% |
| 15 | GSA CAPITAL PARTNERS LLP | 16,673 | $151,000 | 0.0% | 0.1% | +22.7% |
| 16 | STATE STREET CORP | 13,311 | $120,465 | 0.0% | 0.1% | 0.0% |
| 17 | PRUDENTIAL FINANCIAL INCNEW | 13,180 | $119,279 | 0.0% | 0.1% | new |
| 18 | HRT FINANCIAL LPNEW | 12,453 | $112,000 | 0.0% | 0.1% | new |
| 19 | NORTHERN TRUST CORPNEW | 11,650 | $105,433 | 0.0% | 0.1% | new |
| 20 | CITADEL ADVISORS LLC | 11,061 | $100,102 | 0.0% | 0.1% | -57.4% |
| 21 | BlackRock, Inc. | 10,908 | $98,718 | 0.0% | 0.1% | +24.6% |
| 22 | Vanguard Global Advisers, LLCNEW | 3,359 | $30,399 | 0.0% | 0% | new |
| 23 | Steward Partners Investment Advisory, LLC | 714 | $6,462 | 0.0% | 0% | 0.0% |
| 24 | UBS Group AG | 544 | $4,924 | 0.0% | 0% | +3785.7% |
| 25 | ROYAL BANK OF CANADANEW | 98 | $1,000 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.